NEBULA GENOMICS

Company Overview

Nebula Genomics, founded in 2018, offers whole-genome sequencing services to the consumer market. In August 2021, ProPhase Labs Inc. acquired Nebula Genomics.

Nebula Genomics addresses genetic data privacy through its secure data management platform, which combines blockchain-enabled transparency with privacy-preserving computing.

In February 2020, Nebula launched a 30x whole-genome sequencing product for the DTC market segment. This product accurately reads out the more than 6 billion letters in the human genome, generating a thousand-fold more information and enabling more comprehensive reporting on traits and ancestry. Nebula offers this product in partnership with BGI, using its MGI DNBSeq T-series high-throughput sequencing technology and its global network of sequencing centers.

Individuals who purchase the 30x whole-genome sequencing retain full control of their genomic data, receive weekly updated reports based on recent scientific discoveries, get an in-depth ancestry analysis and can explore their data using browser-based genomic discovery tools.

In June 2019, Nebula formed an alliance with EMD Serono, the biopharmaceutical business of Merck KGaA in the U.S. and Canada. The agreement allowed EMD Serono to access genomic data on Nebula’s blockchain-based network of genomic data sharing.

In September 2020, Nebula Genomics formed an alliance with Oasis Labs, a provider of data privacy software. Oasis Labs markets a blockchain-based product called Parcel that enables third parties like Nebula to give consumers control of their personal data generated on those companies’ platforms.

The objective of this partnership is to address the privacy concerns that exist in the genetic testing industry.

Company's Business Segments

• Genome Sequencing : The company provides access to affordable Whole Genome Sequencing and develops technology to safeguard genomic data privacy.